Status: Recruiting
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Participants needed: 27
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Akouos, Inc.Updated: Apr 6, 2026Locations: 4
Eligibility criteria
Presence of unilateral, progressive vestibular schwannoma. [+8]